BACKGROUND: Plasmodium malariae is considered a minor malaria parasite, although its global disease burden is underappreciated. The aim of this study was to develop an induced blood-stage malaria (IBSM) model of P. malariae to study parasite biology, diagnostic assays, and treatment. METHODS: This clinical trial involved 2 healthy subjects who were intravenously inoculated with cryopreserved P. malariae-infected erythrocytes. Subjects were treated with artemether-lumefantrine after development of clinical symptoms. Prior to antimalarial therapy, mosquito-feeding assays were performed to investigate transmission, and blood samples were collected for rapid diagnostic testing and parasite transcription profiling. Serial blood samples were collected for biomarker analysis. RESULTS: Both subjects experienced symptoms and signs typical of early malaria. Parasitemia was detected 7 days after inoculation, and parasite concentrations increased until antimalarial treatment was initiated 25 and 21 days after inoculation for subjects 1 and 2 respectively (peak parasitemia levels, 174 182 and 50 291 parasites/mL, respectively). The parasite clearance half-life following artemether-lumefantrine treatment was 6.7 hours. Mosquito transmission was observed for 1 subject, while in vivo parasite transcription and biomarkers were successfully profiled. CONCLUSIONS: An IBSM model of P. malariae has been successfully developed and may be used to study the biology of, diagnostic testing for, and treatment of this neglected malaria species. CLINICAL TRIALS REGISTRATION: ACTRN12617000048381.
BACKGROUND:Plasmodium malariae is considered a minor malaria parasite, although its global disease burden is underappreciated. The aim of this study was to develop an induced blood-stage malaria (IBSM) model of P. malariae to study parasite biology, diagnostic assays, and treatment. METHODS: This clinical trial involved 2 healthy subjects who were intravenously inoculated with cryopreserved P. malariae-infected erythrocytes. Subjects were treated with artemether-lumefantrine after development of clinical symptoms. Prior to antimalarial therapy, mosquito-feeding assays were performed to investigate transmission, and blood samples were collected for rapid diagnostic testing and parasite transcription profiling. Serial blood samples were collected for biomarker analysis. RESULTS: Both subjects experienced symptoms and signs typical of early malaria. Parasitemia was detected 7 days after inoculation, and parasite concentrations increased until antimalarial treatment was initiated 25 and 21 days after inoculation for subjects 1 and 2 respectively (peak parasitemia levels, 174 182 and 50 291 parasites/mL, respectively). The parasite clearance half-life following artemether-lumefantrine treatment was 6.7 hours. Mosquito transmission was observed for 1 subject, while in vivo parasite transcription and biomarkers were successfully profiled. CONCLUSIONS: An IBSM model of P. malariae has been successfully developed and may be used to study the biology of, diagnostic testing for, and treatment of this neglected malaria species. CLINICAL TRIALS REGISTRATION: ACTRN12617000048381.
Authors: Romuald Agonhossou; Romaric Akoton; Yannelle A Dossou; Euripide Avokpaho; Dollon N J Mbama; Terence S Boussougou-Sambe; Nongley N Francis; Cyrille Ndo; Francine Ntoumi; Charles S Wondji; Ayola A Adegnika; Steffen Borrmann; Saadou Issifou; Luc S Djogbénou Journal: Parasitol Res Date: 2022-01-04 Impact factor: 2.289
Authors: Robert K M Choy; A Louis Bourgeois; Christian F Ockenhouse; Richard I Walker; Rebecca L Sheets; Jorge Flores Journal: Clin Microbiol Rev Date: 2022-07-06 Impact factor: 50.129
Authors: Stephen D Woolley; Melissa Fernandez; Maria Rebelo; Stacey A Llewellyn; Louise Marquart; Fiona H Amante; Helen E Jennings; Rebecca Webster; Katharine Trenholme; Stephan Chalon; Joerg J Moehrle; James S McCarthy; Bridget E Barber Journal: Malar J Date: 2021-02-16 Impact factor: 2.979
Authors: Rebecca Webster; Silvana Sekuloski; Anand Odedra; Stephen Woolley; Helen Jennings; Fiona Amante; Katharine R Trenholme; Julie Healer; Alan F Cowman; Emily M Eriksson; Priyanka Sathe; Jocelyn Penington; Adam J Blanch; Matthew W A Dixon; Leann Tilley; Michael F Duffy; Alister Craig; Janet Storm; Jo-Anne Chan; Krystal Evans; Anthony T Papenfuss; Louis Schofield; Paul Griffin; Bridget E Barber; Dean Andrew; Michelle J Boyle; Fabian de Labastida Rivera; Christian Engwerda; James S McCarthy Journal: BMC Med Date: 2021-11-22 Impact factor: 8.775
Authors: Anand Odedra; Lachlan Webb; Louise Marquart; Laurence J Britton; Stephan Chalon; Joerg J Moehrle; Nicholas M Anstey; Timothy William; Matthew J Grigg; David G Lalloo; Bridget E Barber; James S McCarthy Journal: Am J Trop Med Hyg Date: 2020-11 Impact factor: 2.345
Authors: Eniyou C Oriero; Adeola Y Olukosi; Olabisi A Oduwole; Abdoulaye Djimde; Umberto D'Alessandro; Martin M Meremikwu; Alfred Amambua-Ngwa Journal: Am J Trop Med Hyg Date: 2020-10-22 Impact factor: 3.707